References

Liver cancer: an evolving challenge reaching research maturity

10.1002/hep.22259 · 2008 · External reference

The anti-angiogenic basis of metronomic chemotherapy

10.1038/nrc1369 · 2004 · External reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

10.1056/nejmoa011954 · 2002 · External reference

The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer

2003 · External reference

High-dose chemotherapy for breast cancer: the French PEGASE experience

10.1177/107327480301000105 · 2003 · External reference

Repopulation of cancer cells during therapy: an important cause of treatment failure

10.1038/nrc1650 · 2005 · External reference

Tumor angiogenesis: therapeutic implications

10.1056/nejm197111182852108 · 1971 · External reference

What is the evidence that tumors are angiogenesis dependent?

10.1093/jnci/82.1.4 · 1990 · External reference

The implications of angiogenesis for the biology and therapy of cancer metastasis

10.1016/0092-8674(94)90187-2 · 1994 · External reference

Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study

10.1038/sj.bjc.6600318 · 2002 · External reference

Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery

10.1593/neo.12208 · 2012 · External reference

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

10.1002/bies.950130106 · 1991 · External reference

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

10.1172/jci8829 · 2000 · External reference

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

2000 · External reference

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

10.1172/jci9872 · 2000 · External reference

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

10.1182/blood-2005-04-1422 · 2005 · External reference

10.1593/tlo.11124 · 2011 · Admitted local publication

Cancer survival in Africa, Asia, the Caribbean and Central America: database and attributes

2011 · External reference

Has the time come for metronomics in low-income and middle-income countries?

10.1016/s1470-2045(13)70056-1 · 2013 · External reference

Global cancer statistics

2011 · External reference

Estimating the world cancer burden: Globocan 2000

10.1002/ijc.1440 · 2001 · External reference

Benign and malignant nodules in cirrhotic livers: distinction based on blood supply

10.1148/radiology.178.2.1846240 · 1991 · External reference

Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings

10.2214/ajr.173.5.10541091 · 1999 · External reference

Vascular changes in hepatocellular carcinoma

10.1002/ar.20668 · 2008 · External reference

Management of hepatocellular carcinoma

10.1002/hep.20933 · 2005 · External reference

Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection

10.1053/j.gastro.2010.12.032 · 2011 · External reference

Sorafenib in advanced hepatocellular carcinoma

10.1056/nejmoa0708857 · 2008 · External reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial

10.1016/s1470-2045(08)70285-7 · 2009 · External reference

Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan

10.1111/j.1872-034x.2010.00706.x · 2010 · External reference

Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome

10.5114/aoms.2011.23408 · 2011 · External reference

Manganese-enhanced MRI predicts the histological grade of hepatocellular carcinoma in potential surgical candidates

10.1016/j.crad.2010.08.007 · 2011 · External reference

Surveillance and early diagnosis of hepatocellular carcinoma

10.1016/s1590-8658(10)60509-9 · 2010 · External reference

Hepatocellular carcinoma

10.1016/s0140-6736(03)14964-1 · 2003 · External reference

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases

10.1002/cncr.10694 · 2002 · External reference

Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis

10.1111/j.1365-2036.2010.04379.x · 2010 · External reference

Medical treatment of hepatocellular carcinoma

10.1016/s0889-8553(21)00333-2 · 1987 · External reference

Immunotherapy of HCC

10.2174/157488708783330549 · 2008 · External reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival

10.1053/jhep.2003.50047 · 2003 · External reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

10.1016/s0140-6736(02)08649-x · 2002 · External reference

Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy

10.1634/theoncologist.12-12-1425 · 2007 · External reference

Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma

1999 · External reference

A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma

10.1093/jnci/dji315 · 2005 · External reference

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin

10.1200/jco.2006.08.4046 · 2007 · External reference

Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients

10.1016/0016-5085(95)90402-6 · 1995 · External reference

Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial

1995 · External reference

Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma

10.1097/00004836-199804000-00010 · 1998 · External reference

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

10.1002/cncr.20368 · 2004 · External reference

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

10.1002/cncr.10607 · 2002 · External reference

A phase 2 study of cisplatin in patients with hepatocellular carcinoma

10.1159/000227142 · 1993 · External reference

5-Fluorouracil and alpha-interferonin hepatocellular carcinoma

10.1097/00000421-199604000-00009 · 1996 · External reference

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial

10.3109/07357909509024907 · 1995 · External reference

Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study

1986 · External reference

Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma

1987 · External reference

A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group

1989 · External reference

Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study

1987 · External reference

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum

10.1016/s1470-2045(04)01508-6 · 2004 · External reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

10.1158/0008-5472.can-04-1443 · 2004 · External reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors

10.1200/jco.2005.06.124 · 2005 · External reference

BAY 43-9006 inhibition of oncogenic RET mutants

10.1093/jnci/djj069 · 2006 · External reference

Current strategy for staging and treatment: the BCLC update and future prospects

10.1055/s-0030-1247133 · 2010 · External reference

Targeted therapies for hepatocellular carcinoma

10.1053/j.gastro.2011.03.006 · 2011 · External reference

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

10.1158/0008-5472.can-05-4411 · 2006 · External reference

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

10.1158/1535-7163.mct-09-0960 · 2010 · External reference

Acute tubulointerstitial nephritis due to Salmonella typhimurium infection

10.1016/j.ejim.2004.05.009 · 2004 · External reference

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase

10.1158/0008-5472.can-05-0646 · 2005 · External reference

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

10.1182/blood-2004-06-2410 · 2005 · External reference

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

10.1038/labinvest.2012.65 · 2012 · External reference

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

10.1158/0008-5472.can-06-4238 · 2007 · External reference

Antiangiogenesis enhances intratumoral drug retention

10.1158/0008-5472.can-10-3242 · 2011 · External reference

Docetaxel versus paclitaxel for antiangiogenesis

10.1089/152581602753448577 · 2002 · External reference

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells

10.1158/0008-5472.can-04-2624 · 2005 · External reference

A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy

10.1097/jto.0b013e3182121c09 · 2011 · External reference

Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts

10.1016/j.canlet.2008.03.008 · 2008 · External reference

10.1593/tlo.12295 · 2013 · Admitted local publication

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide

10.1593/neo.101174 · 2011 · External reference

Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate

10.1002/anr.1780320903 · 1989 · External reference

The microtubule-affecting drug paclitaxel has antiangiogenic activity

1996 · External reference

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs

2002 · External reference

Antiangiogenesis is produced by nontoxic doses of vinblastine

10.1182/blood.v94.12.4143 · 1999 · External reference

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

10.1097/00001813-200301000-00003 · 2003 · External reference

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)

10.1002/ijc.10907 · 2003 · External reference

Endogenous inhibitors of angiogenesis

10.1158/0008-5472.can-04-2427 · 2005 · External reference

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

10.1073/pnas.2135406100 · 2003 · External reference

Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1

10.1593/neo.12772 · 2012 · External reference

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression

10.1158/0008-5472.can-03-3126 · 2004 · External reference

CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells

10.1083/jcb.138.3.707 · 1997 · External reference

Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells

1997 · External reference

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1

10.1038/71517 · 2000 · External reference

Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis

10.1023/a:1009018702832 · 1999 · External reference

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

10.1158/1535-7163.mct-09-0274 · 2009 · External reference

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumorinduced mobilization of circulating angiogenic cells

10.1073/pnas.0812801106 · 2009 · External reference

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

10.1042/cs20040370 · 2005 · External reference

The biology of VEGF and its receptors

10.1038/nm0603-669 · 2003 · External reference

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects

10.1093/annonc/mdj066 · 2006 · External reference

A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients

2006 · External reference

Isolation of putative progenitor endothelial cells for angiogenesis

10.1126/science.275.5302.964 · 1997 · External reference

Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization

10.1172/jci6889 · 1999 · External reference

A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature

10.1172/jci24751 · 2006 · External reference

Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy

10.1158/0008-5472.can-04-4337 · 2005 · External reference

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

10.1016/j.cell.2005.02.034 · 2005 · External reference

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells

2003 · External reference

Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells

10.1158/0008-5472.can-09-1101 · 2009 · External reference

CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers

10.1007/s00262-005-0092-8 · 2006 · External reference

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

10.1002/eji.200324181 · 2004 · External reference

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

10.1007/s00262-009-0671-1 · 2009 · External reference

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

10.1007/s00262-006-0225-8 · 2007 · External reference

Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation

10.1158/0008-5472.can-09-1106 · 2009 · External reference

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water

2002 · External reference

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts

2002 · External reference

Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis

10.1038/mt.2010.34 · 2010 · External reference

Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma

10.1593/neo.91872 · 2010 · External reference

Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?

10.1111/j.1365-2613.2009.00684.x · 2010 · External reference

Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis

10.1007/s00280-009-1108-4 · 2010 · External reference

Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy

10.1593/neo.10804 · 2010 · External reference

Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts

10.1007/s00432-012-1270-7 · 2012 · External reference

Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma

10.1593/neo.101186 · 2011 · External reference

Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma

10.3858/emm.2011.43.5.033 · 2011 · External reference

Metronomic chemotherapy: new rationale for new directions

10.1038/nrclinonc.2010.82 · 2010 · External reference

Metronomic chemotherapy for cancer treatment: a decade of clinical studies

10.1007/s00280-013-2125-x · 2013 · External reference

The role of angiogenesis in human non-Hodgkin lymphomas

10.1593/neo.121962 · 2013 · External reference

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

10.1186/1471-2407-6-225 · 2006 · External reference

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

10.1056/nejmoa032792 · 2004 · External reference

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

10.1200/jco.2008.18.3939 · 2009 · External reference

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma

10.1007/s11060-004-1726-y · 2005 · External reference

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults

10.1215/15228517-2007-006 · 2007 · External reference

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

10.1038/sj.bjc.6605412 · 2009 · External reference

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

10.1200/jco.2008.20.7944 · 2009 · External reference

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

10.1007/s12094-008-0254-7 · 2008 · External reference

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

10.1200/jco.2007.12.1939 · 2008 · External reference

Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer

10.1007/s10911-012-9266-0 · 2012 · External reference

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer

10.1007/s00432-008-0443-x · 2009 · External reference

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

10.1016/j.jhep.2010.01.035 · 2010 · External reference

Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil

10.1016/j.jhep.2011.01.032 · 2011 · External reference

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response

10.1002/cncr.24029 · 2009 · External reference

Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis

10.3350/kjhep.2012.18.1.32 · 2012 · External reference

Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

10.1002/cncr.25257 · 2010 · External reference

Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma

10.1159/000336126 · 2012 · External reference

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy

10.1159/000331684 · 2011 · External reference

Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma

10.1177/030089161009600521 · 2010 · External reference

Durable complete response of hepatocellular carcinoma after metronomic capecitabine

10.1177/548.6527 · 2010 · External reference

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

10.1007/s10456-012-9260-6 · 2012 · External reference